Cargando…

Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a hematologic malignancy that affects predominantly older patients, with a median age of diagnosis around 67. Overall prognosis is poor; however, novel targeted therapies that can potentially improve outcomes in these patients have emerged in recent years. Mutations i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Myers, Rebecca A., Wirth, Scott, Williams, Sherry, Kiel, Patrick J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Harborside Press 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347084/ https://www.ncbi.nlm.nih.gov/pubmed/30719396

Ejemplares similares

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
por: Pollyea, Daniel A., et al.
Publicado: (2019)

Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment
por: Reed, Daniel R, et al.
Publicado: (2019)

All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells
por: Kim, Yundeok, et al.
Publicado: (2020)

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies
por: Fathi, Amir T., et al.
Publicado: (2022)

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
por: DiNardo, Courtney D., et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2‐Mutant Acute Myeloid Leukemia
por: Fan, Bin, et al.
Publicado: (2022)

Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy
por: Galkin, Maria, et al.
Publicado: (2019)

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Merchant, Shelby L., et al.
Publicado: (2019)

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis
por: de Botton, Stéphane, et al.
Publicado: (2021)

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
por: Gupta, Charu, et al.
Publicado: (2020)

IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021
Publicado: (2022)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

The Molecular Mechanisms of Resistance to IDH Inhibitors in Acute Myeloid Leukemia
por: Zhuang, Xiaomei, et al.
Publicado: (2022)

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
por: Issa, Ghayas C., et al.
Publicado: (2021)

IDH1/2 mutations in acute myeloid leukemia
por: Byun, Ja Min, et al.
Publicado: (2022)

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
por: Chaturvedi, Anuhar, et al.
Publicado: (2020)

Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
por: Stuani, Lucille, et al.
Publicado: (2021)

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
por: Wang, Feng, et al.
Publicado: (2021)

Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis
por: Chen, Xiu, et al.
Publicado: (2023)

Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro
por: Sarkaria, Shawn M., et al.
Publicado: (2014)

Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemia
por: Zeng, Zhihong, et al.
Publicado: (2021)

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions
por: Wouters, Bas J.
Publicado: (2021)

Highly Sensitive Detection of IDH2 Mutations in Acute Myeloid Leukemia
por: Petiti, Jessica, et al.
Publicado: (2020)

Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects
por: Li, Yan, et al.
Publicado: (2018)

Enasidenib‐induced Sweet syndrome with differentiation syndrome
por: Mohamed, Amr
Publicado: (2021)

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
por: Chaturvedi, A, et al.
Publicado: (2017)

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia
por: Gui, Gege, et al.
Publicado: (2023)

Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition
por: Chen, Chong, et al.
Publicado: (2013)

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
por: de Botton, Stéphane, et al.
Publicado: (2023)

Identification of High-Affinity Small Molecule Targeting IDH2 for the Clinical Treatment of Acute Myeloid Leukemia
por: Sweta, Jajoriya, et al.
Publicado: (2019)

Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
por: Pollyea, Daniel A., et al.
Publicado: (2022)

Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2022)

Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome
por: Annamaraju, Pavan, et al.
Publicado: (2020)

The Frequency and Clinical Significance of IDH1 Mutations in Chinese Acute Myeloid Leukemia Patients
por: Guan, Lixun, et al.
Publicado: (2013)

Transgenic IDH2(R172K) and IDH2(R140Q) zebrafish models recapitulated features of human acute myeloid leukemia
por: Wang, Dandan, et al.
Publicado: (2023)

High Frequency of ASXL1 and IDH Mutations in Young Acute Myeloid Leukemia Egyptian Patients
por: El Nahass, Yasser H, et al.
Publicado: (2022)

Clinical and biological implications of IDH1/2 in acute myeloid leukemia with DNMT3A(mut)
por: Zhang, Xinpei, et al.
Publicado: (2018)

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia
por: Ok, Chi Young, et al.
Publicado: (2019)

Venetoclax-Azacitidine Bridging PTCy-haplo-PBSCT for Refractory Acute Myeloid Leukemia with IDH2 Mutations
por: Daido, Yusuke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1au8u0j9supmjssid385m9ctts